 |
|
Medicines derived from cannabis: a review of adverse events
June 17, 2008Researchers at the McGill University Health Centre (MUHC), McGill University and the University of British Columbia (UBC) determined that medical use of cannabinoids do not cause an increase in serious adverse events, but are associated with an increase in some non-serious adverse events.
Several drugs containing compounds derived from the cannabis plant, or cannibinoids, are available for medical purposes in Canada. As the use of cannabinoid medications increases, so do concerns about their potential to cause "adverse events," or negative side effects. Dr. Mark Ware, Dr. Stan Shapiro and PhD candidate Tongtong Wang of the Research Institute of the McGill University Health Centre and McGill University, and Dr. Jean-Paul Collet of the University of British Columbia examined the nature of these potential adverse events in a study which will be published June 16 in the Canadian Medical Association Journal (CMAJ).
The study was based on the adverse events reported in 31 separate clinical studies of cannabinoid medications conducted between 1966 and 2007. Adverse events were categorized as either serious or non-serious; with serious adverse events defined as those leading to death, hospitalization or disability.
"Overall, we found an 86% increase in the rate of non-serious adverse events among the patients treated with cannabinoids compared to the patients in the control groups," said Ware, a neurosciences researcher at the Research Institute of the MUHC and assistant professor in anesthesia at McGill's Faculty of Medicine The majority of events were mild to moderate in severity.
The majority of non-serious adverse events observed affected the nervous system, mainly dizziness and drowsiness. "Cannabinoids are used as medicines because they are neurologically active, so we expected to see some side effects such as these," said Wang, a PhD candidate in epidemiology and biostatistics at McGill University.
Cannabinoids have been shown to treat chronic pain resulting from diseases such as cancer, multiple sclerosis, arthritis and fibromyalgia, and also to stimulate appetite and relieve nausea. Physicians must weigh the possible benefits of treatment against the possible side effects in an overall attempt to improve the patient's quality of life.
"We have summarized the adverse events from these studies to help educate physicians and patients about the possible risks of medical cannabinoids," said Collet, formerly at McGill's Department of Epidemiology, and now professor at University of British Columbia, senior researcher at the Child & Family Research Institute and Director of the Centre for Applied Health Research and Evaluation at British Columbia Children's Hospital. "We cannot extend these results to smoked cannabis or recreational use. That will require further research."
McGill University Health Centre
"Overall, we found an 86% increase in the rate of non-serious adverse events among the patients treated with cannabinoids compared to the patients in the control groups," said Ware, a neurosciences researcher at the Research Institute of the MUHC and assistant professor in anesthesia at McGill's Faculty of Medicine The majority of events were mild to moderate in severity.
The majority of non-serious adverse events observed affected the nervous system, mainly dizziness and drowsiness. "Cannabinoids are used as medicines because they are neurologically active, so we expected to see some side effects such as these," said Wang, a PhD candidate in epidemiology and biostatistics at McGill University.
Cannabinoids have been shown to treat chronic pain resulting from diseases such as cancer, multiple sclerosis, arthritis and fibromyalgia, and also to stimulate appetite and relieve nausea. Physicians must weigh the possible benefits of treatment against the possible side effects in an overall attempt to improve the patient's quality of life.
"We have summarized the adverse events from these studies to help educate physicians and patients about the possible risks of medical cannabinoids," said Collet, formerly at McGill's Department of Epidemiology, and now professor at University of British Columbia, senior researcher at the Child & Family Research Institute and Director of the Centre for Applied Health Research and Evaluation at British Columbia Children's Hospital. "We cannot extend these results to smoked cannabis or recreational use. That will require further research."
McGill University Health Centre
Cannabinoids Current Events and Cannabinoids News RSSUse of cannabinoids (marijuana) could help post-traumatic stress disorder patients
Use of cannabinoids (marijuana) could assist in the treatment of post-traumatic stress disorder patients. This is exposed in a new study carried out at the Learning and Memory Lab in the University of Haifa's Department of Psychology.
Active ingredients in marijuana found to spread and prolong pain
Imagine that you're working on your back porch, hammering in a nail. Suddenly you slip and hit your thumb instead - hard. The pain is incredibly intense, but it only lasts a moment. After a few seconds (and a few unprintable words) you're ready to start hammering again.
'Cannabis alters human DNA' -- new study
A new study published by University of Leicester researchers has found "convincing evidence" that cannabis smoke damages DNA in ways that could potentially increase the risk of cancer development in humans.
Medicinal marijuana effective for neuropathic pain in HIV
In a double-blind, placebo-controlled clinical trial to assess the impact of smoked medical cannabis, or marijuana, on the neuropathic pain associated with HIV, researchers at the University of California, San Diego School of Medicine found that reported pain relief was greater with cannabis than with a placebo.
Milestone for cannabinoid MS study
The CUPID (Cannabinoid Use in Progressive Inflammatory brain Disease) study at the Peninsula Medical School in Plymouth has reached an important milestone with the news that the full cohort of 493 people with multiple sclerosis (MS) has been recruited to the study.
Schizophrenia linked to dysfunction in molecular brain pathway activated by marijuana
Alterations in a molecular brain pathway activated by marijuana may contribute to the cognitive symptoms of schizophrenia, according to a report in the July issue of Archives of General Psychiatry, one of the JAMA/Archives journals.
Opioids and cannabinoids influence mobility of spermatozoids
A PhD thesis from the University of the Basque Country has concluded that there are opioid and cannabinoid receptors in human sperm and that these influence the mobility of spermatozoid.
U of Minnesota researcher discovers the starting point of sun-induced skin cancer
According to a new study from the University of Minnesota, the earliest event in the development of sun-induced skin cancer may have been identified.
MIT study suggests caution on new anti-obesity drug in kids
Anti-obesity drugs that work by blocking brain molecules similar to those in marijuana could also interfere with neural development in young children, according to a new study from MIT's Picower Institute for Learning and Memory.
New brain cells implicated in machinery of cannabinoid signaling
The brain cells called astrocytes, and not just neurons, are sensitive to the substances called cannabinoids-the active chemicals in marijuana.
More Cannabinoids Current Events and Cannabinoids News Articles
 |
Cannabis and Cannabinoids: Pharmacology, Toxicology, and Therapeutic Potential by Ethan B Russo (Author) Presents an objective and comprehensive description of the state of the art of medicinal cannabis. Contains new and updated data based on international sources. Hardcover, softcover also available. |
 |
Cannabinoids and the Brain by Attila Köfalvi (Author), Attila Köfalvi (Editor) Endocannabinoids control most of the body functions, and in the brain, they modulate neurotransmission, synaptic plasticity, confer neuroprotection, control metabolism, neuro- and neuritogenesis, survival, cognitive and motor functions as well as a plethora of other higher-order brain functions. Their fruitful therapeutic potential is recognized by cannabinoid researchers and pharmaceutical companies, respectively. The aim of this book is to help clinicians, neuroscientists, as well as students, understand the significance of the endocannabinoid system. This book, however, also will be very useful to those who already feel comfortable with the neuroscience of endocannabinoids. The book will introduce the reader to the up-to-date neurobiology of endocannabinoids and related... |
 |
Cannabinoids (Handbook of Experimental Pharmacology) (Volume 168) by Roger G. Pertwee (Editor) The present book is an outstanding summary of many aspects of cannabinoid research. It provides current knowledge about the pharmacology and therapeutic potential of cannabinoids as well as knowledge about the pharmacology, physiology, and pathology of the endogenous cannabinoid systems. The chapters are written by scientists who have made or are still making major contributions to the field. This book may well help generate novel ideas on how to approach the study of emotions. |
 |
The Cannabinoid Receptors (The Receptors) by Patricia H. Reggio (Editor) As research has progressed, the cannabinoid CB 1 and CB 2 receptors have expanded significantly in importance within the neuroscience mainstream. In The Cannabinoid Receptors, leading experts introduce newcomers to the cannabinoid field with chapters covering cannabinoid ligand synthesis and structure activity relationships, the molecular pharmacology of the cannabinoid receptors and the endocannabinoid system, and ultimately, the whole animal pharmacology and therapeutic applications for cannabinoid drugs. Adding to those key topics, the book also examines the current direction of the field with chapters on new putative cannabinoid receptors and challenges for future research. As a part of The Receptors ™ series, this volume highlights its receptor with the most thorough, focused... |
 |
Medicinal Uses of Cannabis and Cannabinoids by Geoffrey W. Guy (Editor), Brian A. Whittle (Editor), Philip J. Robson (Editor) In recent years, cannabis research has moved beyond its use as an illegal recreational drug to consider its potential as a therapeutic substance, particularly in serious chronic illnesses such as multiple sclerosis. Although there is a considerable body of primary literature relating to the medicinal use of cannabis, much of the published work concerns anecdotal reports. This title describes all the contemporary research findings relating to the medicinal use of cannabis and cannabinoids, and reports on the pharmacology, formulation, safety and efficacy of cannabis as a therapeutic agent. This should be a useful reference for pharmacists, doctors, pharmacologists and all other healthcare professionals with an interest in pain control. |
 |
Cannabinoids in Nature and Medicine by Didier M. Lambert (Editor) Originally a special issue of Chemistry & Biodiversity, the first part of this volume focuses on the plant Cannabis sativa, its active ingredients, and the discovery of cannabinoid receptors as well as the therapeutic applications of activating, or blocking, the receptors. Following an overview of the plant, its medicinal uses, and its preparations, further chapters cover biosynthetic pathways, pharmacological properties, cannabis-based medicine, toxicology, cannabis prohibition and clinical situations where blocking the cannabinoid receptors might be beneficial. The second part covers the journey from humans to plants, analyzing anandamide, as well as other endocannabinoids and endocannabinoid congeners, biosynthetic pathways, current knowledge of FAAH-1, FAAH-2, monoglyceride... |
|
Synthesis of Novel Cannabinoid CBI Receptor Ligands by Teija Parkkari (Author) English-language text. 148 pp. | |
 |
Marijuana and Cannabinoid Research: Methods and Protocols (Methods in Molecular Medicine) by Emmanuel S. Onaivi (Editor) A cutting-edge collection of readily reproducible in vitro and in vivo methods to elucidate the mechanisms associated with cannabinoid function in health and disease. The techniques can be used in studies across the board from genes to behavior. The molecular neurobiological methods are invaluable in analyzing the structure, the polymorphisms, and the molecular expression of the cannabinoid receptors (CBrs), as well as their association with polysubstance abuse. There are also methods for localizing cannabinoid receptors in different systems, visualizing cannabinoid effects using brain slice imaging and elctrophysiological approaches, and designing and synthesizing cannabinoids and endocannabinoids. The protocols follow the successful Methods in Molecular Medicine™ series format, each... |
 |
Marijuana and the Cannabinoids (Forensic Science and Medicine) by Mahmoud A. ElSohly (Editor) Marijuana and the Cannabinoids presents a compendium of research into the botany, chemistry, and pharmacology of cannabis and the medicinal aspects of the cannabinoids. While medicinal use of Cannabis sativa L. has been reported for over 5000 years, interest in its medicinal potential and controversy surrounding its illicit use have grown exponentially since the identification of the chemical structure of the plant's active constituent (D9-THC) in 1964. This volume presents the findings of researchers on the forefront of this emerging and controversial field of study. Chapter 1 is an overview of Cannabis and natural Cannabis medicines, while Chapter 2 focuses on the chemistry and analysis of phytocannabinoids and other Cannabis constituents. Chapter 3 discusses the potential of chemical... |
 |
Cannabinoids: Webster's Timeline History, 1968 - 2007 by Icon Group International (Author) Webster's bibliographic and event-based timelines are comprehensive in scope, covering virtually all topics, geographic locations and people. They do so from a linguistic point of view, and in the case of this book, the focus is on "Cannabinoids," including when used in literature (e.g. all authors that might have Cannabinoids in their name). As such, this book represents the largest compilation of timeline events associated with Cannabinoids when it is used in proper noun form. Webster's timelines cover bibliographic citations, patented inventions, as well as non-conventional and alternative meanings which capture ambiguities in usage. These furthermore cover all parts of speech (possessive, institutional usage, geographic usage) and contexts, including pop culture, the arts, social... |
| © 2009 BrightSurf.com |